Obagi Medical has embarked on a strategic collaboration with Platinum Dermatology Partners, aiming to drive real-world evidence through the ALOHA Program. This partnership underscores the commitment of both organizations to elevate standards in aesthetic dermatology.
Selection of Platinum Dermatology Partners
Platinum Dermatology Partners has been chosen as the inaugural partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. This selection stems from Platinum’s strong dedication to clinical evidence and its extensive network of practices, making it an ideal fit for this initiative.
Generating Real-World Data
The primary goal of this collaboration is to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into practical applications within everyday dermatological practices. Michael Pennington, CEO and Co-founder of Platinum, emphasizes the importance of this partnership, noting that the clinical expertise of their injectors provides invaluable insights into how trial data performs in real-world settings.
Hands-On Experience with Obagi Products
The ALOHA Real-World Program is structured to give Platinum providers direct experience with Obagi saypha MagIQ™ while evaluating comprehensive Obagi protocols. This hands-on approach is designed to enhance patient satisfaction and foster stronger relationships between patients and their providers within the Platinum network.
Standardized Evaluation Process
To ensure consistency and reliability, the program includes a structured evaluation process across multiple Platinum practices. Standardized data capture will facilitate the collection of insights and observations, setting a benchmark for the effectiveness of the new product and its protocols.
Initial Findings to be Showcased
Platinum Dermatology Partners is set to present initial findings at its upcoming annual Platinum Summit in Dallas this September. These findings will highlight the benefits of the new injectable and its associated protocols, demonstrating the real-world impact of integrating this innovative solution across the Platinum network.
Commitment to Clinical Evidence
Drew Fine, U.S. General Manager of the Professional Channel at Obagi, articulates the significance of this partnership in the context of launching the new injectable. By anchoring the launch in robust clinical evidence and education, Obagi Medical aims to ensure that the ALOHA program not only serves as a platform for a differentiated launch strategy but also reinforces its commitment to innovation in skincare and injectable aesthetics.
Innovative Technology Behind Obagi saypha MagIQ™
Obagi saypha MagIQ™, developed by Croma-Pharma GmbH, is at the forefront of this initiative. Utilizing proprietary MACRO Core Technology, it features a stable three-dimensional hyaluronic acid matrix designed to deliver natural-looking results. This technology is characterized by high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile.
Legacy of Obagi Medical
With a legacy spanning over 35 years, Obagi Medical has established itself as a leader in advanced skincare. Initially recognized for its expertise in treating hyperpigmentation, the brand has expanded its product line to address a variety of skin concerns, including premature aging and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024, Obagi Medical continues to empower individuals to achieve healthy, beautiful skin.
Empowering Exceptional Dermatology
Platinum Dermatology Partners, headquartered in Dallas, Texas, is dedicated to empowering the practice of exceptional dermatology. With over 120 locations and nearly 400 providers across several states, the organization fosters a collaborative environment focused on elevating patient care and benefiting the dermatology specialty.
In conclusion, the collaboration between Obagi Medical and Platinum Dermatology Partners exemplifies a progressive step toward enriching real-world evidence in aesthetic dermatology. By leveraging clinical expertise and innovative technology, both organizations are poised to redefine standards in patient care and outcomes in the field.
- The ALOHA Program aims to translate clinical trial data into practical applications.
- Platinum Dermatology Partners is the first platform partner selected for this initiative.
- Initial findings from the program will be shared at the Platinum Summit in September.
- Obagi saypha MagIQ™ features advanced technology for enhanced aesthetic results.
- This collaboration underscores the commitment to elevating standards in skincare and patient experience.
Read more → www.manilatimes.net